Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Financial Statements

  Year Ending Dec 2017 (Update) Year Ending Dec 2016 (Restated) Year Ending Dec 2015 (Restated) Year Ending Dec 2014 (Update)
Net Sales -117.43 -98.33 -52.58 -97.86
Gross Revenue 245.80 244.77 215.14 284.69
Revenue 128.37 146.44 162.56 186.83
Total Revenue 128.37 146.44 162.56 186.83
Cost of Revenue 47.22 35.84 27.69 27.04
Cost of Revenue, Total 47.22 35.84 27.69 27.04
Gross Profit 81.15 110.60 134.87 159.79
Selling/General/Administrative Expense 71.36 76.94 76.47 87.36
Labor & Related Expense 12.90 11.48 11.60 10.05
Selling/General/Administrative Expenses, Total 84.27 88.42 88.06 97.41
Research & Development 65.90 59.12 51.07 69.66
Amortization of Intangibles, Operating 27.65 25.95 38.32 24.29
Depreciation/Amortization 27.65 25.95 38.32 24.29
Purchased R&D Written-Off
Other Unusual Expense (Income)
Unusual Expense (Income)
Total Operating Expense 225.03 209.33 205.15 218.40
Operating Income -96.66 -62.89 -42.59 -31.57
Interest Expense - Non-Operating -8.07 -9.69 -9.21 -8.72
Interest Expense, Net Non-Operating -8.07 -9.69 -9.21 -8.72
Interest Income (Expense), Net Non-Operating 1.27 0.26 0.14 0.13
Interest Income (Expense), Net-Non-Operating, Total -6.80 -9.44 -9.07 -8.58
Other Non-Operating Income (Expense) -4.57 0.24 -0.57 -3.38
Other, Net -4.57 0.24 -0.57 -3.38
Net Income Before Taxes -108.03 -72.08 -52.24 -43.53
Income Tax – Total -55.68 -2.31 0.41 2.19
Income After Tax -52.35 -69.77 -52.64 -45.72
Minority Interest
Net Income Before Extraordinary Items -52.35 -69.77 -52.64 -45.72
Extraordinary Item -38.90
Total Extraordinary Items -38.90
Net Income -91.25 -69.77 -52.64 -45.72
Income Available to Common Excluding Extraordinary Items -52.35 -69.77 -52.64 -45.72
Income Available to Common Stocks Including Extraordinary Items -91.25 -69.77 -52.64 -45.72
Basic Weighted Average Shares 85.12 72.82 64.88 64.71
Basic EPS Excluding Extraordinary Items -0.62 -0.96 -0.81 -0.71
Basic EPS Including Extraordinary Items -1.07 -0.96 -0.81 -0.71
Dilution Adjustment
Diluted Net Income -91.25 -69.77 -52.64 -45.72
Diluted Weighted Average Shares 85.12 72.82 64.88 64.71
Diluted EPS Excluding Extraordinary Items -0.62 -0.96 -0.81 -0.71
Diluted EPS Including Extraordinary Items -1.07 -0.96 -0.81 -0.71
DPS - Common Stock Primary Issue
Gross Dividends - Common Stock -- -- -- --
Total Special Items
Normalized Income Before Taxes -108.03 -72.08 -52.24 -43.53
Effect of Special Items on Income Taxes
Income Taxes Excluding Impact of Special Items -55.68 -2.31 0.41 2.19
Normalized Income After Taxes -52.35 -69.77 -52.64 -45.72
Normalized Income Available to Common -52.35 -69.77 -52.64 -45.72
Basic Normalized EPS -0.62 -0.96 -0.81 -0.71
Diluted Normalized EPS -0.62 -0.96 -0.81 -0.71
Amortization of Intangibles, Supplemental 27.65 25.95 38.32 24.29
Depreciation, Supplemental 0.33 0.55 0.70 1.10
Interest Expense, Supplemental 8.07 9.69 9.21 8.72
Rental Expense, Supplemental 1.60 1.50 1.70 1.90
Stock-Based Compensation, Supplemental 13.11 11.62 11.66 1.76
Minority Interest, Supplemental
Research & Development Expense, Supplemental 65.90 59.12 51.07 69.66
Audit-Related Fees, Supplemental 1.22 1.23 1.54
Audit-Related Fees 0.07 0.19 0.02
Tax Fees, Supplemental 0.17 0.31 0.01
Gross Margin 63.22 75.52 82.97 85.53
Operating Margin -75.30 -42.94 -26.20 -16.90
Pretax Margin -84.15 -49.22 -32.13 -23.30
Effective Tax Rate
Net Profit Margin -40.78 -47.64 -32.38 -24.47
Normalized EBIT -96.66 -62.89 -42.59 -31.57
Normalized EBITDA -68.69 -36.39 -3.57 -6.18
Current Tax - Domestic -10.61 -2.00 0.11 1.53
Current Tax - Foreign 0.01 0.01 0.15 0.03
Current Tax - Local -0.94 -0.22 0.01 0.13
Current Tax - Total -11.54 -2.21 0.27 1.68
Deferred Tax - Domestic -44.16 -0.09 0.11 0.50
Deferred Tax - Foreign -- -- -- --
Deferred Tax - Local 0.02 -0.01 0.03 0.01
Deferred Tax - Total -44.14 -0.10 0.14 0.50
Income Tax - Total -55.68 -2.31 0.41 2.19
Defined Contribution Expense - Domestic 0.91 1.03
Total Pension Expense 0.91 1.03

In millions of USD (except for per share items)

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright West LLC. Minimum 15 minutes delayed.